Contact information Registered office and corporate headquarters address AstraZeneca PLC 15 Stanhope Gate London W1K 1LN UK Tel: 44 0 20 7304 5000 Fax: 44 0 20 7304 5183 R&D headquarters address AstraZeneca AB R&D Headquarters SE-151 85 Sdertlje Sweden Tel: 46 0 8 553 260 00 Fax: 46 0 8 553 290 00 Investor relations contacts UK and Sweden: as above or e-mail IR@astrazeneca.
com US: Investor Relations AstraZeneca Pharmaceuticals LP 1800 Concord Pike PO Box 15438 Wilmington fide 19850-5438 US Tel: 1 302 886 3000 Fax: 1 302 886 2972 Registrar and transfer office Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA UK Tel in the UK : 0870 600 3956 Tel outside the UK : 44 121 415 7033 Swedish securities registration centre VPC AB PO Box 7822 SE-103 97 Stockholm Sweden Tel: 46 0 8 402 9000 US depositary JPMorgan Chase Bank PO Box 43013 Providence RI 02940-3013 US Tel toll free in the US : 888 697 8018 Tel: 1 781 575 4328 astrazeneca.
com Annual Review 2004 thinking people thinking performance Annual Review 2004 01 astrazeneca.
com The year in brief AstraZeneca is one of the worlds Group sales up 9% at constant exchange rates to $21.4 billion strong leading pharmaceutical companies.
sales performance from key growth products up 30% to $11.2 billion We focus our skills, experience Operating profit up 15% at constant exchange rates to $4.8 billion EPS and resources on six therapy pre-exceptional items up 18% areas: cancer, cardiovascular, gastrointestinal, infection, Dividend increased by 18% to $0.94 for the full year neuroscience, and respiratory and inflammation important Nexium sales reached $3.9 billion, up 15% areas of healthcare that represent the majority of the worldwide Seroquel sales increased by 33% to just over $2 billion burden of disease.
We have a broad range of products for Symbicort sales totalled $797 million, up 32% these areas and a commitment to delivering a flow of new Expanded use of Arimidex in the treatment of early stage breast cancer medicines designed to meet the underpinned 48% increase in sales to $811 million needs of patients and the healthcare professionals who treat them.
Crestor sales totalled $908 million despite challenging environment.
Sales impacted by allegations regarding the products safety.
Clinical trials experience and post-marketing surveillance continue to support our belief that the safety profile is in line with other marketed statins FDA decision not to approve Exanta.
In the EU, where Exanta already marketed for acute indications, more data have been requested before approval of use in chronic indication can be considered Results of ISEL clinical study for Iressa showed no statistically significant increase in survival of overall population.
Data suggest survival benefits in patient populations of East Asian origin and non-smokers R&D investment totalled $3.8 billion.
40% more projects in clinical development phases 1 and 2 than in 2003.
31 projects in pre-clinical testing 26 in 2003 Important strategic alliance with Cambridge Antibody Technology to discover and develop human antibody therapeutics in inflammatory disorders Global clinical trials website on track for launch in the first quarter of 2005.
This will provide a detailed, publicly available, scientific, non-promotional summary of clinical trials conducted for products approved since AstraZeneca was formed in 1999 Appointment of Executive Director for Development as part of accelerated significant programme of change to optimise the contribution of our development and regulatory functions Contents Chairmans statement 02 Board of Directors 18 Strategy 03 Summary Directors report 20 Chief Executives review 04 Remuneration policy 22 Financial highlights 05 Summary financial review 24 AstraZeneca in brief 05 Summary financial statements 27 Discovery 07 Auditors statement 27 Development 08 Group profit and loss account 28 Development pipeline 09 Group balance sheet 30 Sales and marketing 10 Statement of Group cash flow 31 Key products 10 Dividends 32 Supply 12 Earnings per share 32 Product strategy & licensing 13 Emoluments of Directors 33 People 14 Group financial record 34 Therapy area review 16 Shareholder information 35
